The Patent Finder

Hospira, Inc.

29 patents currently held · Updated Nov 15, 2026
89 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Nov 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 14, 2027
    The maintenance fee for Port assembly for mixing the contents of two containers (US 9,079,686) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
  • 1 fee due Jun 24, 2027
    The maintenance fee for Cartridge assembly for an injection system (US 10,512,591) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 3 fees due Oct 19 to 28, 2027 · next Oct 19

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,488,311Port closure system for intravenous fluid container
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,563,253Injection device and method of assembly and activation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,569,036Injection device and method of assembly and activation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,091,727Snap-over clamshell protective port cap
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,242,158Dexmedetomidine premix formulation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,324,260Methods of treating pediatric patients using dexmedetomidine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,338,470Dexmedetomidine premix formulation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,436,033Methods of treatment using a dexmedetomidine premix formulation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,455,527Methods of treatment using a dexmedetomidine premix formulation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,507,542Methods of treating pediatric patients using dexmedetomidine
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 29 patents shown.
Pro members see all 29.
Pro members: see all 29 patents
Also on record, not counted in the 29: 89 patents in force now held by others · 41 lapsed for an unpaid fee · 293 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 11 abandoned · 29 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited